Anavex Life Sciences (AVXL) Accumulated Expenses (2018 - 2025)

Anavex Life Sciences (AVXL) has 8 years of Accumulated Expenses data on file, last reported at $2.9 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Expenses fell 62.14% year-over-year to $2.9 million; the trailing twelve-month figure through Dec 2025 stood at $2.9 million (down 62.14% YoY), and the FY2025 full-year result was $3.9 million, up 105.82% from the prior year.
• Accumulated Expenses retreated to $2.9 million in Q4 2025, from $3.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $9.6 million in Q1 2025 to a low of $511234.0 in Q1 2022.
• A 5-year average of $5.2 million and a median of $5.5 million in 2021 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses sank 85.87% in 2022 and surged 1234.58% in 2023, its largest moves.
• Tracing AVXL's Accumulated Expenses over 5 years: stood at $5.5 million in 2021, then increased by 29.23% to $7.0 million in 2022, then gained by 3.45% to $7.3 million in 2023, then gained by 6.12% to $7.7 million in 2024, then plunged by 62.14% to $2.9 million in 2025.
• Business Quant data shows AVXL's Accumulated Expenses at $2.9 million in Q4 2025, $3.9 million in Q3 2025, and $3.9 million in Q2 2025.